| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ... New England Journal of Medicine 369 (18), 1691-1703, 2013 | 4453 | 2013 |
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses S Jones, X Zhang, DW Parsons, JCH Lin, RJ Leary, P Angenendt, ... science 321 (5897), 1801-1806, 2008 | 3963 | 2008 |
| Pancreatic cancer M Hidalgo New England Journal of Medicine 362 (17), 1605-1617, 2010 | 2957 | 2010 |
| A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development A Jimeno, G Feldmann, A Suárez-Gauthier, Z Rasheed, A Solomon, ... Molecular cancer therapeutics 8 (2), 310-314, 2009 | 1417* | 2009 |
| Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1344 | 2015 |
| Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab S Khambata-Ford, CR Garrett, NJ Meropol, M Basik, CT Harbison, S Wu, ... Journal of clinical oncology 25 (22), 3230-3237, 2007 | 1290 | 2007 |
| Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ... Journal of clinical oncology 19 (13), 3267-3279, 2001 | 1184 | 2001 |
| Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma MB Atkins, M Hidalgo, WM Stadler, TF Logan, JP Dutcher, GR Hudes, ... Journal of clinical oncology 22 (5), 909-918, 2004 | 1132 | 2004 |
| Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014 | 1073 | 2014 |
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ... Journal of Clinical Oncology 29 (34), 4548, 2011 | 1007 | 2011 |
| Development of matrix metalloproteinase inhibitors in cancer therapy M Hidalgo, SG Eckhardt Journal of the National Cancer Institute 93 (3), 178-193, 2001 | 1007 | 2001 |
| DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer CA Iacobuzio-Donahue, B Fu, S Yachida, M Luo, H Abe, CM Henderson, ... Journal of clinical oncology 27 (11), 1806, 2009 | 945 | 2009 |
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of … D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu Journal of clinical oncology 22 (1), 77-85, 2004 | 922 | 2004 |
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ... Journal of Clinical Oncology 23 (23), 5294-5304, 2005 | 781 | 2005 |
| The rapamycin-sensitive signal transduction pathway as a target for cancer therapy M Hidalgo, EK Rowinsky Oncogene 19 (56), 6680-6686, 2000 | 731 | 2000 |
| Developing inhibitors of the epidermal growth factor receptor for cancer treatment V Grunwald, M Hidalgo Journal of the National Cancer Institute 95 (12), 851-867, 2003 | 612 | 2003 |
| Pancreatic cancer: from state-of-the-art treatments to promising novel therapies I Garrido-Laguna, M Hidalgo Nature reviews Clinical oncology 12 (6), 319-334, 2015 | 480 | 2015 |
| Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity LA DeGraffenried, WE Friedrichs, DH Russell, EJ Donzis, AK Middleton, ... Clinical cancer research 10 (23), 8059-8067, 2004 | 447 | 2004 |
| Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma ZA Rasheed, J Yang, Q Wang, J Kowalski, I Freed, C Murter, SM Hong, ... Journal of the National Cancer Institute 102 (5), 340-351, 2010 | 440 | 2010 |
| An in vivo platform for translational drug development in pancreatic cancer B Rubio-Viqueira, A Jimeno, G Cusatis, X Zhang, C Iacobuzio-Donahue, ... Clinical cancer research 12 (15), 4652-4661, 2006 | 419 | 2006 |
